[Lipodystrophy syndrome. Therapeutic progress is still pending].
A common problem seen with the long-term use of highly active antiretroviral therapy (HAART) is the HIV-associated lipodystrophy syndrome. Clinical signs include a loss of peripheral subcutaneous fatty tissue, an increase in visceral or local fat, and altered glucose and lipid metabolism. The physical changes frequently impair quality of life, and the patient's adherence to treatment regimens. Metabolic changes may possibly represent cardiovascular risks with incalculable consequences over the long term. Although the lipodystrophy syndrome was first described in 1998. It still lacks a definition. So far, therapeutic strategies have remained ineffective or have had only limited success. Proposed treatments include general recommendations (diet, physical exercise, etc.), changing the antiretroviral therapy, and treatment with metabolically active medication.
Weber
K
K
Abteilung Klinische Immunologie, Medizinische Hochschule Hannover. weber-r.klaus@mh-hannover.de
Heiken
H
H
Stoll
M
M
Schmidt
R E
RE
Behrens
G
G
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D004359:Drug Therapy, Combination; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000175:diagnosis* / Q000628:therapy; D006801:Humans; D012885:Skinfold Thickness; D016896:Treatment Outcome
D019380:Anti-HIV Agents